Avery Therapeutics

Executive Summary

Avery Therapeutics is a private, preclinical-stage biotechnology company headquartered in Tucson, Arizona, dedicated to developing tissue-engineered therapeutics for muscle diseases and injuries. Its lead product candidate, MyCardia, is a cell-free, off-the-shelf tissue patch designed to treat heart failure by restoring cardiac muscle function. The company was founded in 2014 and focuses on leveraging its proprietary platform to address the high unmet need in cardiovascular regenerative medicine. While Avery has not disclosed total funding or valuation, its position in the tissue engineering space and focus on heart failure—a major global health burden—positions it as a potential player in the emerging field of cardiac repair. The company's progress has been limited to preclinical development, and it has not yet initiated clinical trials. Key risks include early-stage technology validation, manufacturing scale-up, and regulatory pathway uncertainty. However, if successful, MyCardia could offer a transformative alternative to heart transplants or mechanical support devices.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for MyCardia40% success
• Q2 2027Series A or B financing round50% success
• Q1 2028IND filing or FDA meeting for first-in-human trial30% success